Novo Nordisk said its experimental drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes.
In this article
Novo Nordisk
said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study.
The drugmaker’s Denmark-listed shares were up 2.5%.
Amycretin, the company’s next-generation obesity drug, has a dual-mode action, targeting the gut hormone GLP-1 and a pancreatic hormone called amylin.
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose
Phase 3 trial results showed the once-weekly Cagrilintide monotherapy injection helped patients reduce their weight by 11.8% on…
Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of…
Amycretin also improved participants’ blood sugar levels in positive sign for Danish company’s treatment pipeline
The early data is a boost to the Danish drugmaker's hopes of winning back more market share from Eli Lilly this year in the…
Novo Nordisk shares slide after Ozempic pill fails in Alzheimer’s trials
